ovarian cancer drug

Update news ovarian cancer drug

Vietnamnet global

FDA expands use of AstraZeneca/Merck ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer

Vietnamnet global

Tesaro's ovarian cancer drug study succeeds, shares soar

Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares to a record high.